Bringing you the latest science in psychiatry
About PsychX and ECNP
We believe in making mental health expertise readily available to all. This vision led to the creation of PsychX, a platform to champion both emerging and established voices in the mental health domain. Every month, we host short online discussions spanning various mental health topics, making knowledge accessible without registration fees or hidden costs.
Join these high-relevance free online sessions, featuring monthly explorations into both clinical and experimental facets of psychiatry.
In 2022, PsychX and ECNP started collaborating. As from 2023, all PsychX talks were transferred to ECNP.
How to join the talks
Click on the button below to join:
or via the direct meeting link.
Meeting ID: 854 0080 8569
Mark your calendars for our lineup! We convene every first Monday of the month.
4 March 2024, 16.30-17.30 CET (Central European Time)
Modernising the concept of ADHD
Barbara Franke, The Netherlands
Among persons with attention-deficit/hyperactivity disorder (ADHD), some thrive, whereas many have difficult lives, characterized by social and professional problems and comorbidity. Pressing issues around ADHD in today’s society are a lack of personalized treatment and patient self-management, and stigma. A modernized concept of ADHD is urgently needed, one that builds on an understanding of the bio-psycho-social-societal basis of the condition and is balanced, with an eye for both limitations and strengths, balancing risks and resilience. Through availability of big data, advances in artificial intelligence, and the advent of mHealth such reconceptualization is now possible, allowing us to address the pressing issues.
Barbara Franke is professor of molecular psychiatry at Radboud University in Nijmegen, the Netherlands, and the head of the department of cognitive neuroscience at Radboud University Medical Center. Trained as a molecular biologist and geneticist, she is one of the internationally leading scientists in the field of biological psychiatry. Her focus is on neurodevelopmental conditions, especially ADHD, and their mental and somatic comorbidities in children and adults. Using interdisciplinary and convergence mental health-based team science approaches, it is her explicit goal to contribute to improving the diagnosis, monitoring, and treatment of psychiatric conditions and to their re-conceptualization
8 April 2024, 16.30-17.30 CEST (Central European Summer Time)
Embracing complexity: studying mental health problems as systems, not syndromes
Eiko Fried, The Netherlands
Systems are everywhere: the climate system, the train system, the healthcare system, and the political system. In the last two decades, complex systems approaches have enabled considerable advances in explanation and prediction across a range of disciplines, including ecology, meteorology, and medicine. Here I introduce a systems approach to mental health problems, where disorders like depression are conceptualised as emergent states arising from dynamic interactions among bio-psycho-social elements. I show that this perspective provides utility for description, prediction, understanding, and treatment. It offers new lenses through which to study mental illness (e.g., attractor states, phase transitions), and new levers to treat them (e.g., early warning signals, novel treatment targets).
Eiko Fried obtained his PhD in clinical psychology at the Free University of Berlin, followed by four years of postdoctoral training in methodology. He now works as associate professor in clinical psychology at Leiden University. Eiko’s research takes place at the intersection of clinical psychology, psychiatry, and complexity science, and his interests are how to best measure, predict, and understand mental health problems. His lab is currently focused on developing a personalized early warning system for depression (www.warn-d.com). Eiko loves burnt coffee and fast computers, and you can find his blog, publications and data online (www.eiko-fried.com).
6 May 2024, 16.30-17.30 CEST
Common contributors to morbidity in substance use
Sandra Sanchez-Roige, USA
Outline and bio to be announced
3 June 2024, 16.30-17.30 CEST
Democratizing normative modeling for neuroimaging data
Sophia Frangou, United Kingdom
In the last two decades, neuroimaging techniques have become essential tools for the study of the human brain. However, there is currently a lack of reference standards to accurately quantify individual differences in neuroimaging metrics across the human lifespan. The presentation will introduce a major advance in addressing aforementioned knowledge gaps related to brain morphometry. CentileBrain is web platform that enables the measurement of brain deviations using an international reference (>37,000 study participants aged 3-90 years, from more than 80 research sites).
Dr. Sophia Frangou serves as professor of psychiatry at the Icahn School of medicine and as chair in brain health and associate Dean for research for the faculty of medicine at the University of British Columbia. Her work focuses on elucidating the brain correlates of psychopathology and cognition across the lifespan in healthy individuals and persons with schizophrenia and bipolar disorder. Dr. Frangou has published over 300 articles and has received numerous awards including the 2019 Colvin Prize for outstanding achievement in mood disorders research from the brain and behavior research foundation and the 2020 Educator Award and the 2022 George N. Thompson Award, both from the society of biological psychiatry.
1 July 2024, 16.30-17.30 CEST (Central European Summer Time)
Less is more – a differentiated approach to antipsychotic medication in Soteria
Martin Voss, Germany
Soteria (ancient Greek: healing, welfare, preservation, rescue) refers to an inpatient treatment approach for accompanying people in psychotic crises, in which so-called "milieu therapy" and close personal support ("being with") are at the center of the treatment. Because of its calming, relaxing and setting, Soteria can help to minimize doses of antipsychotic medication which in turn improves adherence and long term outcomes in first episode schizophrenia. The lecture provides an overview of the origin and development of the Soteria idea and uses the example of the Soteria Berlin at Charité University Hospital/St. Hedwig Hospital (Berlin, Germany) to show how such a concept can be established in the hospital and become part of standard psychiatric care.
Having studied medicine and philosophy in Aachen and Berlin; Martin's initial training in neurology was at Charité Berlin. A postdoctoral researcher at the institute of neurology, UCL, London, UK from 2003-2005. Training in psychiatry from 2006; he obtained the role of consultant psychiatrist at the department of psychiatry and psychotherapy, Charité University Medicine and St. Hedwig Hospital in Berlin, Germany. Martin Voss is the founder of Soteria Berlin (2013) where his roles span: clinical supervisor, psychotherapist (psychodynamic psychotherapy), Head of the research division ''Psychotic Disorders“. He is a lecturer in psychiatry (Charité Medical School) and an internationally recognized researcher (main research Interest: self-disorders in schizophrenia, sense of self-agency, embodiment, effects of architecture and design on mental disorders and well-being).
Date to be announced
Topic to be announced
Rene Kahn, USA
René Kahn is chair of psychiatry at the Icahn School of Medicine at Mount Sinai since 2017. After completing medical school in the Netherlands, he was trained as a psychiatrist and neurologist in Utrecht and Amsterdam. He subsequently completed his psychiatry residencies at Mount Sinai Hospital and then worked as chief of the psychiatry research unit at the Bronx VA. In 1993 he became chair of psychiatry at the University Hospital Utrecht, going on to lead the Brain Center Rudolf Magnus, which combines research in basic neuroscience, psychiatry and neurology. Kahn has published over 950 research papers with a web of science H index of 107. He has been continuously funded for over 25 years by NIMH, the EU, the Stanley Foundation, and other organisations. He has served on several neuroscience grant review boards. René Kahn received several honors, such as a Fulbright Scholarship, membership of the Royal Netherlands Academy of Arts and Sciences, the ECNP Neuropsychopharmacology Award, an honorary doctorate at Semmelweis University in Budapest, Hungary and the lifetime achievement award of the Netherlands Psychiatric Association. He was knighted in the Netherlands in 2018. He served as treasurer and vice-president of ECNP and as president of the Schizophrenia International Research Society. He is a fellow of the American College of Neuropsychopharmacology.
PsychX Programme Committee
Visit this page to find out about the PsychX Programme Committee and its members, goals, composition and time commitment.
View here previous PsychX talks.